Diabetes Clinical Trials in New York

Showing 541-560 of 582 trials

The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study

NCT00547482

The main purpose of this research study is to investigate whether the TANTALUS II System is effective in improving glycemic (blood sugar) control in subjects who have type 2 diabetes (high blood sugar) and are overweight. The research will also evaluate the impact on weight loss and will study other health conditions related to obesity. This research study involves an experimental system. The experimental system is the TANTALUS System, which consists of the implantable portion that includes the implantable pulse generator (IPG) and three pairs of implantable leads. There are also three external parts (items that are used outside your body): the programmer, the charger, and the Patient Wand.

Type 2 Diabetes MellitusOverweight

MetaCure (USA), Inc.300 participantsStarted Sep 2007

La Jolla / San Diego, California, United States • Los Angeles, California, United States • Denver, Colorado, United States +7 more locations

TERMINATEDPhase 3< 1 mile

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330

This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.

Diabetes Mellitus, Type 2

AstraZeneca1,100 participantsStarted Mar 2005

Birmingham, Alabama, United States • Columbiana, Alabama, United States • Mobile, Alabama, United States +168 more locations

The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

Diabetes Trials in Other Cities

Diabetes Control and Complications Trial (DCCT)

Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)

Prevention of Type 2 Diabetes Mellitus in Children

GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes

Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety

Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

GALLANT 6 Tesaglitazar vs. Pioglitazone

A Study for Type 2 Diabetic Patients

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study

Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Other Conditions in New York